<DOC>
	<DOCNO>NCT02520076</DOCNO>
	<brief_summary>Islet transplantation relatively new procedure use people difficult control Type 1 diabetes . Insulin produce cell ( islet ) isolate pancreas donate next kin person brain dead . After cell prepared , islet transplant recipient 's liver produce insulin . Patients receive islet transplant take medication suppresses immune system prevent rejection islet tissue . The investigator also learn general inflammation time transplant fully control standard medication . The investigator believe inflammation may cause islet cell death around time transplant . Due islet death around time transplant , recipient need 2 3 separate transplant procedure . The investigator study use Alpha-1 Antitrypsin ( AAT ) islet transplant decrease amount cell death cause general inflammation . In study , investigator hope decrease need one transplant procedure control inflammation , transplant , Alpha-1 Antitrypsin ( Aralast NP ) . Alpha-1 Antitrypsin protein make healthy human help prevent tissue damage time inflammation . Alpha-1 Antitrypsin obtain healthy plasma donor . There study Islet Transplant monkey use medication show protect islet inflammation . This study involve use Alpha-1 Antitrypsin addition current Standard Care medication use Islet Transplant .</brief_summary>
	<brief_title>Aralast NP Islet Transplant</brief_title>
	<detailed_description>METHODS &amp; PROCEDURES : This clinical trial non-randomized , open-label , single arm , prospective trial ass efficacy AAT prevent non-immunologic loss transplant islet mass single-donor islet transplant . Enrolled patient ( n=12 ) participate study 1 year , outcome assess islet isolation , 90 day post-transplant 1 year post-transplant . The current Standard Care treatment Islet Transplant include induction ( Alemtuzumab/Basiliximab ) long-term immunosuppression ( Prograf/Cellcept ) . The engraftment regimen include anti-inflammatory medication ( Etanercept/Anakinra ) intravenous insulin heparin . We utilize current Islet Standard Care Protocol . The additional intervention use pilot trial addition investigational agent , alpha-1-antitrypsin islet processing , culture , patient treatment pre- post-transplant . Islet Dosage Culture Islets treat AAT ( final dilution 0.5mg/mL ) throughout isolation culture process . Islet treatment include : - Flushing superior mesenteric artery splenic artery ( final dilution 0.5mg/mL ) - Culturing AAT ( final dilution 0.5mg/mL ) Participant Dosing Subjects undergoing intraportal clinical islet transplantation receive treatment ( AAT 120mg/kg intravenously , base Day -1 admission weight round near 20mg ) follow time point : - Day -1 prior transplant - Day 3 post-transplant - Day 7 post-transplant - Day 14 post-transplant Recipient management include transplant procedure , postoperative care , immunosuppression medication , post-transplant monitoring follow standard care protocol . SCOPE &amp; DURATION : Recruitment take place Clinical Islet Transplant Program University Alberta Hospital , Edmonton , Alberta . Participants ( N=12 ) adult patient , assess deem appropriate activate wait list islet transplantation . Anticipated duration enrollment 12 month , follow-up 90 day 12 month . In pilot study control data obtain Standard Care control cohort comparison . We also obtain 2 year 3 year long-term follow-up data standard care test . This long-term follow review data collect within 3 year post-transplant include follow : patient graft survival data , biochemical data routine blood work , routine cause imaging , metabolic testing , initiation intervention treat complication , report adverse serious adverse event . STUDY FOLLOWUP : As follow-up , study use number blood test parameter use clinical program . We obtain follow information regard participant outcome routine blood testing , metabolic testing , clinic visit : - Complete blood count ( CBC ) -differential monitor white red blood cell - Liver function test - Kidney function test - Blood sugar test , include Hemoglobin A1c ( HbA1c ) estimate average blood sugar 3 month . - C-peptide testing , chemical produce healthy , work islet . These clinic occur weekly x 4weeks , 1 month , 3 month , 6 , month 12 month . Participants annual clinic visit , standard care . Clinic visit include vital sign , physician assessment , review record blood glucose record , determination patient require insulin become insulin independent set criterion base blood sugar test glucose record .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>To eligible participant must Type 1 Diabetes Mellitus ( T1DM ) 5 year , complicate least 1 follow situation persist despite intensive insulin management effort : 1 . Reduced awareness hypoglycemia , define absence adequate autonomic symptom plasma glucose level &lt; 3.0 mmol/L , indicate , 1 episode severe hypoglycemia require third party assistance within 12 month , Clarke score ≥4 , HYPO score ≥1,000 , lability index ( LI ) ≥400 combine HYPO/LI &gt; 400/ &gt; 300 . 2 . Metabolic instability , characterize erratic blood glucose level interfere daily activity 1 hospital visit diabetic ketoacidosis last 12 month . Participants must capable understand purpose risk study must sign statement informed consent . 1 . Hypersensitivity Aralast NP , history immunoglobulin A ( IgA ) deficiency , assess low IgA ( &lt; 0.70 g/L ) . 2 . Severe coexist cardiac disease , characterize one condition : ( ) recent ( within past 6months ) myocardial infarction ; ( b ) leave ventricular ejection fraction &lt; 30 % ; ( c ) evidence ischemia functional cardiac exam . 3 . Active alcohol substance abuse , include cigarette smoking ( must abstinent 6 month prior list transplant ) . 4 . Psychiatric disorder make subject suitable candidate transplantation , ( e.g. , schizophrenia , bipolar disorder , major depression unstable uncontrolled current medication ) . 5 . History nonadherence prescribe regimen . 6 . Active infection include Hepatitis C , Hepatitis B , HIV , tuberculosis ( TB ) ( subject positive purify protein derivative ( PPD ) perform within one year enrollment , history adequate chemoprophylaxis ) . 7 . Any history , current malignancy except squamous basal skin cancer . 8 . BMI &gt; 35 kg/m2 screen visit . 9 . Age le 18 great 68 year . 10 . Measured glomerular filtration rate &lt; 60 mL/min/1.73 m2 . 11 . Presence history macroalbuminuria ( &gt; 300 mg/g creatinine ) . 12 . Clinical suspicion nephritic ( hematuria , active urinary sediment ) rapidly progress renal impairment ( e.g . Increase serum creatinine 25 % within last 36 month ) . 13 . Baseline Hb &lt; 105 g/L woman , &lt; 120 g/L men . 14 . Baseline screen liver function test ( LFT ) outside normal range , exception uncomplicated Gilbert 's Syndrome . An initial LFT panel value &gt; 1.5 time upper limit normal ( ULN ) exclude patient without retest ; retest value ULN 1.5 time ULN make , value remain elevated normal limit , patient exclude . 15 . Untreated proliferative retinopathy . 16 . Positive pregnancy test , intent future pregnancy male subject ' intent procreate , failure follow effective contraceptive measure , presently breastfeed . 17 . Previous transplant evidence significant sensitization panel reactive antibody ( PRA ) ( discretion investigator ) . 18 . Insulin requirement &gt; 1.0 U/kg/day 19 . Hemoglobin A1c ( HbA1c ) &gt; 12 % . 20 . Uncontrolled hyperlipidemia [ fast LDL cholesterol &gt; 3.4 mmol/L , treat untreated ; and/or fast triglyceride &gt; 2.3 mmol/L ) ] . 21 . Under treatment medical condition require chronic use steroid . 22 . Use coumadin anticoagulant therapy ( except aspirin ) subject prothrombin time / international normalize ratio ( PT/INR ) &gt; 1.5 . 23 . Untreated Celiac disease . 24 . Patients Graves disease exclude unless previously adequately treated radioiodine ablative therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Islet Transplantation</keyword>
</DOC>